Patents by Inventor Gerald W. Becker

Gerald W. Becker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5919902
    Abstract: A leptin binding protein, inter-alpha-trypsin inhibitor heavy chain related protein (IHRP), specifically binds leptin, the obesity gene product. The specific leptin binding proteins enable modulation of free leptin levels, immobilization and assay of bound/free leptin.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, John E. Hale
  • Patent number: 5594101
    Abstract: The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, John E. Hale, Warren C. MacKellar
  • Patent number: 5352769
    Abstract: This disclosure relates to new compounds and to a process for the controlled conversion of such compounds to produce a Protein that comprises an amino acid sequence which is useful as a precursor to human insulin or to a modified human insulin, the amino terminus portion of which sequence does not define a cathepsin C dipeptide removal stop point. The compounds have the formula Met-Y-Protein in which Y is Tyr or Arg.
    Type: Grant
    Filed: April 6, 1992
    Date of Patent: October 4, 1994
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, Thomas C. Furman, Warren C. MacKellar, James P. McDonough
  • Patent number: 5126249
    Abstract: This disclosure relates to new compounds and to a process for the controlled conversion of such compounds to produce a Protein that comprises an amino acid sequence which is useful as a precursor to human insulin or to a modified human insulin, the amino terminus portion of which sequence does not define a cathepsin C dipeptide removal stop point. The compounds have the formula Met-Y-Protein in which Y is Tyr or Arg.
    Type: Grant
    Filed: May 9, 1989
    Date of Patent: June 30, 1992
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, Thomas C. Furman, Warren C. MacKellar, James P. McDonough
  • Patent number: 5079345
    Abstract: This specification describes modified growth hormone having substantially diminished insulin-like and diabetogenic potencies relative to the native hormone with retention of substantially all of the anabolic potency of the native hormone. The modified growth hormone has the following structure: (a) elimination of from 1-5 to 1-19 amino acid residues from the amino terminus of the hormone; (b) cleavage of a peptide bond at any point from the carboxy moiety of residue 127 to residue 153; and (c) optionally, elimination of one or more of amino acid residues 128-152 of the hormone.
    Type: Grant
    Filed: August 19, 1988
    Date of Patent: January 7, 1992
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, Carl J. Shaar
  • Patent number: 5068317
    Abstract: A sulfoxide of human growth hormone has been produced and characterized. The sulfoxide derivative arises from a selective oxidation of Met.sup.14. The sulfoxide exhibits full biological activity.
    Type: Grant
    Filed: March 15, 1988
    Date of Patent: November 26, 1991
    Assignee: Eli Lilly and Company
    Inventors: Gerald W. Becker, Ralph M. Riggin